This retrospective analysis of the 2001-2009 Nationwide Inpatient Sample quantifies the hospital cost burden of periprosthetic joint infection following THA and TKA in the US. It projects that burden forward to 2020 using Poisson modeling against Census Bureau population data. The central question: how much does PJI cost the US health care system, and where is that number headed?
PJI is the most resource-intensive complication of total joint arthroplasty. Each infected revision costs a US hospital roughly $24,000-$31,000 in institutional costs alone — and that number excludes the surgeon, the anesthesiologist, the rehab team, and any outpatient pharmaceutical treatment. The real per-episode burden is higher than any published figure.
When you're counseling a patient preoperatively about arthroplasty risks, infection deserves the same airtime as DVT or dislocation. It affects 1 in 40-50 procedures, it's getting more common each year, and the standard treatment. Two-stage exchange. Only works 65%-90% of the time. A meaningful fraction of infected patients will face salvage procedures.
The scale of this problem also justifies the cost of prevention. Antibiotic-impregnated cement, preoperative decolonization protocols, and laminar flow optimization are expensive. But the baseline they're competing against is half a billion dollars annually in 2009 and climbing fast.
The authors note that these cost figures systematically understate the true burden, since NIS data captures only hospital charges. Keep that in mind when citing this paper's numbers in policy or quality improvement discussions.
This retrospective analysis of the 2001-2009 Nationwide Inpatient Sample quantifies the hospital cost burden of periprosthetic joint infection following THA and TKA in the US. It projects that burden forward to 2020 using Poisson modeling against Census Bureau population data. The central question: how much does PJI cost the US health care system, and where is that number headed?
PJI is the most resource-intensive complication of total joint arthroplasty. Each infected revision costs a US hospital roughly $24,000-$31,000 in institutional costs alone — and that number excludes the surgeon, the anesthesiologist, the rehab team, and any outpatient pharmaceutical treatment. The real per-episode burden is higher than any published figure.
When you're counseling a patient preoperatively about arthroplasty risks, infection deserves the same airtime as DVT or dislocation. It affects 1 in 40-50 procedures, it's getting more common each year, and the standard treatment. Two-stage exchange. Only works 65%-90% of the time. A meaningful fraction of infected patients will face salvage procedures.
The scale of this problem also justifies the cost of prevention. Antibiotic-impregnated cement, preoperative decolonization protocols, and laminar flow optimization are expensive. But the baseline they're competing against is half a billion dollars annually in 2009 and climbing fast.
The authors note that these cost figures systematically understate the true burden, since NIS data captures only hospital charges. Keep that in mind when citing this paper's numbers in policy or quality improvement discussions.